-
1
-
-
0018891451
-
Epidemiology of acromegaly in the Newcastle region
-
1
-
Alexander L, Appleton D, Hall R, Ross W, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980;12(1):71-9.
-
(1980)
Clin Endocrinol
, vol.12
, pp. 71-79
-
-
Alexander, L.1
Appleton, D.2
Hall, R.3
Ross, W.4
Wilkinson, R.5
-
2
-
-
33748652910
-
Drug Insight: Primary medical therapy of acromegaly
-
Katznelson L. Drug Insight: primary medical therapy of acromegaly. Nat Clin Pract Endocrinol Metab 2006;2:109-17.
-
(2006)
Nat Clin Pract Endocrinol Metab
, vol.2
, pp. 109-117
-
-
Katznelson, L.1
-
3
-
-
1442326975
-
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
-
1
-
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocr Rev 2004;25(1):102-52.
-
(2004)
Endocr Rev
, vol.25
, pp. 102-152
-
-
Colao, A.1
Ferone, D.2
Marzullo, P.3
Lombardi, G.4
-
4
-
-
0025700486
-
Acromegaly
-
14
-
Melmed S. Acromegaly. N Engl J Med 1990;322(14):941-1012.
-
(1990)
N Engl J Med
, vol.322
, pp. 941-1012
-
-
Melmed, S.1
-
5
-
-
23844540615
-
Long-acting somatostatin analog therapy of acromegaly: A meta-analysis
-
8
-
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005;90(8):4465-73.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 4465-4473
-
-
Freda, P.U.1
Katznelson, L.2
Van Der Lely, A.J.3
Reyes, C.M.4
Zhao, S.5
Rabinowitz, D.6
-
6
-
-
0029826419
-
Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
-
4
-
Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;45(4):407-13.
-
(1996)
Clin Endocrinol
, vol.45
, pp. 407-413
-
-
Sheaves, R.1
Jenkins, P.2
Blackburn, P.3
Huneidi, A.H.4
Afshar, F.5
Medbak, S.6
-
7
-
-
0023929086
-
Arthropathy in acromegalic patients before and after treatment: A long-term follow-up study
-
5
-
Dons RF, Rosselet P, Pastakia B, Doppman J, Gorden P. Arthropathy in acromegalic patients before and after treatment: a long-term follow-up study. Clin Endocrinol 1988;28(5):515-24.
-
(1988)
Clin Endocrinol
, vol.28
, pp. 515-524
-
-
Dons, R.F.1
Rosselet, P.2
Pastakia, B.3
Doppman, J.4
Gorden, P.5
-
9
-
-
0026004767
-
Sleep apnea and systemic hypertension: A causal association review
-
2
-
Hoffstein V, Chan CK, Slutsky AS. Sleep apnea and systemic hypertension: A causal association review. Am J Med 1991;91(2):190-6.
-
(1991)
Am J Med
, vol.91
, pp. 190-196
-
-
Hoffstein, V.1
Chan, C.K.2
Slutsky, A.S.3
-
10
-
-
0026887059
-
Snoring, sleep apnea syndrome, and stroke
-
7 Suppl 6
-
Palomäki H, Partinen M, Erkinjuntti T, Kaste M. Snoring, sleep apnea syndrome, and stroke. Neurology 1992;42 7 Suppl 6:75-81.
-
(1992)
Neurology
, vol.42
, pp. 75-81
-
-
Palomäki, H.1
Partinen, M.2
Erkinjuntti, T.3
Kaste, M.4
-
11
-
-
0028829472
-
Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly
-
12
-
Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995;80(12):3395-402.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 3395-3402
-
-
Melmed, S.1
Ho, K.2
Klibanski, A.3
Reichlin, S.4
Thorner, M.5
-
12
-
-
0025991116
-
Plasma concentrations of atrial natriuretic hormone in acromegaly: Relationship to hypertension
-
3
-
Soszynski P, Slowinska-Srzednicka J, Zgliczynski S. Plasma concentrations of atrial natriuretic hormone in acromegaly: relationship to hypertension. Acta Endocrinol (Copenh) 1991;125(3):268-72.
-
(1991)
Acta Endocrinol (Copenh)
, vol.125
, pp. 268-272
-
-
Soszynski, P.1
Slowinska-Srzednicka, J.2
Zgliczynski, S.3
-
13
-
-
0018747016
-
Abnormal plasma catecholamine responses in acromegalics
-
5
-
Van Loon GR. Abnormal plasma catecholamine responses in acromegalics. J Clin Endocrinol Metab 1979;48(5):784-9.
-
(1979)
J Clin Endocrinol Metab
, vol.48
, pp. 784-789
-
-
Van Loon, G.R.1
-
14
-
-
0029964803
-
Growth hormone, the insulin-like growth factor system, and the kidney
-
5
-
Feld S, Hirschberg R. Growth hormone, the insulin-like growth factor system, and the kidney. Endocr Rev 1996;17(5):423-80.
-
(1996)
Endocr Rev
, vol.17
, pp. 423-480
-
-
Feld, S.1
Hirschberg, R.2
-
15
-
-
0038173653
-
Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects
-
2-3
-
Moller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res 2003;13(2-3):55-74.
-
(2003)
Growth Horm IGF Res
, vol.13
, pp. 55-74
-
-
Moller, J.1
-
16
-
-
0033306152
-
Diurnal Rhythm of Plasma Catecholamines in Acromegaly
-
7
-
Bondanelli M, Ambrosio MR, Franceschetti P, Margutti A, Trasforini G, degli Uberti EC. Diurnal Rhythm of Plasma Catecholamines in Acromegaly. J Clin Endocrinol Metab 1999;84(7):2458-67.
-
(1999)
J Clin Endocrinol Metab
, vol.84
, pp. 2458-2467
-
-
Bondanelli, M.1
Ambrosio, M.R.2
Franceschetti, P.3
Margutti, A.4
Trasforini, G.5
Degli Uberti, E.C.6
-
17
-
-
0035664930
-
Effects of growth hormone on renal tubular handling of sodium in healthy humans
-
6
-
Hansen TK, Moller J, Thomsen K, Frandsen E, Dall R, Jorgensen JO, et al. Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 2001;281(6):E1326-332.
-
(2001)
Am J Physiol Endocrinol Metab
, vol.281
-
-
Hansen, T.K.1
Moller, J.2
Thomsen, K.3
Frandsen, E.4
Dall, R.5
Jorgensen, J.O.6
-
18
-
-
0035470209
-
Pathogenesis and prevalence of hypertension in acromegaly
-
4
-
Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 2001;4(4):239-49.
-
(2001)
Pituitary
, vol.4
, pp. 239-249
-
-
Bondanelli, M.1
Ambrosio, M.R.2
Degli Uberti, E.C.3
-
20
-
-
0027159276
-
-
Etxabe J, Gaztambide S, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. 1993;16(3):181-7.
-
(1993)
Acromegaly: An Epidemiological Study
, vol.16
, Issue.3
, pp. 181-187
-
-
Etxabe, J.1
Gaztambide, S.2
Latorre, P.3
Vazquez, J.A.4
-
21
-
-
0031774361
-
Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
-
10
-
Swearingen B, Barker FG II, Katznelson L, Biller BMK, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83(10):3419-26.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 3419-3426
-
-
Swearingen, B.1
Barker II, F.G.2
Katznelson, L.3
Biller, B.M.K.4
Grinspoon, S.5
Klibanski, A.6
-
23
-
-
0035404392
-
Clinical perspective: Acromegaly and cancer: Not a problem
-
7
-
Melmed S. Clinical perspective: acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86(7):2929-34.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 2929-2934
-
-
Melmed, S.1
-
25
-
-
0030904951
-
Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension
-
4
-
Lopez-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension. J Clin Endocrinol Metab 1997;82(4):1047-53.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 1047-1053
-
-
Lopez-Velasco, R.1
Escobar-Morreale, H.F.2
Vega, B.3
Villa, E.4
Sancho, J.M.5
Moya-Mur, J.L.6
-
26
-
-
0031772696
-
Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results
-
10
-
Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998;83(10):3411-8.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 3411-3418
-
-
Abosch, A.1
Tyrrell, J.B.2
Lamborn, K.R.3
Hannegan, L.T.4
Applebury, C.B.5
Wilson, C.B.6
-
27
-
-
0028817158
-
Does treatment of acromegaly affect life expectancy
-
11
-
Bates A. Does treatment of acromegaly affect life expectancy. Metabolism 1995;44(11):1-5.
-
(1995)
Metabolism
, vol.44
, pp. 1-5
-
-
Bates, A.1
-
29
-
-
0242351840
-
Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: Mortality, morbidity, and the effects of hospital and surgeon volume
-
10
-
Barker FG II, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003;88(10):4709-19.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 4709-4719
-
-
Barker II, F.G.1
Klibanski, A.2
Swearingen, B.3
-
30
-
-
15944401695
-
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
-
3
-
Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005;152(3):379-87.
-
(2005)
Eur J Endocrinol
, vol.152
, pp. 379-387
-
-
Nomikos, P.1
Buchfelder, M.2
Fahlbusch, R.3
-
31
-
-
0034857211
-
Surgical management of GH-Secreting pituitary adenomas: An outcome study using modern remission criteria
-
9
-
Kreutzer J, Vance ML, Lopes MBS, Laws ER Jr. Surgical management of GH-Secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001;86(9):4072-7.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 4072-4077
-
-
Kreutzer, J.1
Vance, M.L.2
Lopes, M.B.S.3
Laws Jr., E.R.4
-
32
-
-
0032909272
-
How many surgeons to operate on acromegalic patients
-
5
-
Clayton. How many surgeons to operate on acromegalic patients. Clin Endocrinol 1999;50(5):557-9.
-
(1999)
Clin Endocrinol
, vol.50
, pp. 557-559
-
-
Clayton1
-
34
-
-
0030884349
-
Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor i in patients with acromegaly
-
10
-
Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor i in patients with acromegaly. J Clin Endocrinol Metab 1997;82(10):3187-91.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 3187-3191
-
-
Barkan, A.L.1
Halasz, I.2
Dornfeld, K.J.3
Jaffe, C.A.4
Friberg, R.D.5
Chandler, W.F.6
-
35
-
-
0034458010
-
Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly
-
7
-
Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000;85(7):2476-82.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 2476-2482
-
-
Biermasz, N.R.1
Van Dulken, H.2
Roelfsema, F.3
-
36
-
-
0034455933
-
Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure
-
5
-
Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000;85(5):2068-71.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 2068-2071
-
-
Powell, J.S.1
Wardlaw, S.L.2
Post, K.D.3
Freda, P.U.4
-
37
-
-
0031812096
-
Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy
-
6
-
Landolt A, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998;88(6):1002-8.
-
(1998)
J Neurosurg
, vol.88
, pp. 1002-1008
-
-
Landolt, A.1
Haller, D.2
Lomax, N.3
Scheib, S.4
Schubiger, O.5
Siegfried, J.6
-
38
-
-
23844500632
-
Outcome of gamma knife radiosurgery in 82 patients with acromegaly: Correlation with initial hypersecretion
-
8
-
Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90(8):4483-8.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 4483-4488
-
-
Castinetti, F.1
Taieb, D.2
Kuhn, J.M.3
Chanson, P.4
Tamura, M.5
Jaquet, P.6
-
39
-
-
15944427116
-
The antitumoral effects of somatostatin analog therapy in acromegaly
-
3
-
Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90(3):1856-63.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 1856-1863
-
-
Bevan, J.S.1
-
40
-
-
0033729273
-
Signal transduction of somatostatin receptors negatively controlling cell proliferation
-
Ferjoux G, Bousquet C, Cordelier P, Bali NL, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000;94:205-10.
-
(2000)
J Physiol Paris
, vol.94
, pp. 205-210
-
-
Ferjoux, G.1
Bousquet, C.2
Cordelier, P.3
Bali, N.L.4
-
41
-
-
0028929754
-
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
-
5
-
Buscail L, Esteve J, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Nat Acad Sci USA 1995;92(5):1580-4.
-
(1995)
Proc Nat Acad Sci USA
, vol.92
, pp. 1580-1584
-
-
Buscail, L.1
Esteve, J.2
Saint-Laurent, N.3
Bertrand, V.4
Reisine, T.5
O'Carroll, A.6
-
42
-
-
0030794303
-
Characterization of the antiproliferative signal mediated by the somatostatin receptor subtypeásst5
-
17
-
Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtypeásst5. Proc Nat Acad Sci USA 1997;94(17):9343-8.
-
(1997)
Proc Nat Acad Sci USA
, vol.94
, pp. 9343-9348
-
-
Cordelier, P.1
Esteve, J.P.2
Bousquet, C.3
Delesque, N.4
O'Carroll, A.M.5
Schally, A.V.6
-
44
-
-
0036380541
-
Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma
-
4
-
Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002;659(4):200-6.
-
(2002)
Digestion
, vol.659
, pp. 200-206
-
-
Koizumi, M.1
Onda, M.2
Tanaka, N.3
Seya, T.4
Yamada, T.5
Takahashi, Y.6
-
45
-
-
0024317498
-
Octreotide. a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion
-
5
-
Battershill P, Clissold S. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 1989;38(5):658-702.
-
(1989)
Drugs
, vol.38
, pp. 658-702
-
-
Battershill, P.1
Clissold, S.2
-
46
-
-
10444279988
-
Sandostatin(R) LAR(R): A promising therapeutic tool in the management of acromegalic patients
-
Supplement 1
-
Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin(R) LAR(R): A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45 Supplement 1:67-71.
-
(1996)
Metabolism
, vol.45
, pp. 67-71
-
-
Lancranjan, I.1
Bruns, C.2
Grass, P.3
Jaquet, P.4
Jervell, J.5
Kendall-Taylor, P.6
-
47
-
-
4143066821
-
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status
-
2
-
Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol 2004;61(2):209-15.
-
(2004)
Clin Endocrinol
, vol.61
, pp. 209-215
-
-
Cozzi, R.1
Attanasio, R.2
Lodrini, S.3
Lasio, G.4
-
48
-
-
0036111856
-
SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
-
5
-
Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707-16.
-
(2002)
Eur J Endocrinol
, vol.146
, pp. 707-716
-
-
Bruns, C.1
Lewis, I.2
Briner, U.3
Meno-Tetang, G.4
Weckbecker, G.5
-
49
-
-
0032730198
-
Long-acting formulations of somatostatin analogues
-
Suppl 2
-
Anthony L. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol 1999;31 Suppl 2:S216-8.
-
(1999)
Ital J Gastroenterol Hepatol
, vol.31
-
-
Anthony, L.1
-
50
-
-
0036513129
-
Somatuline Autogel: An extended release lanreotide formulation
-
3
-
Lightman S. Somatuline Autogel: an extended release lanreotide formulation. Hosp Med 2002;63(3):162-5.
-
(2002)
Hosp Med
, vol.63
, pp. 162-165
-
-
Lightman, S.1
-
51
-
-
0034974291
-
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
-
6
-
Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86(6):2779-86.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 2779-2786
-
-
Colao, A.1
Ferone, D.2
Marzullo, P.3
Cappabianca, P.4
Cirillo, S.5
Boerlin, V.6
-
52
-
-
7844232389
-
Octreotide as Primary Therapy for Acromegaly
-
9
-
Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as Primary Therapy for Acromegaly. J Clin Endocrinol Metab 1998;83(9):3034-40.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 3034-3040
-
-
Newman, C.B.1
Melmed, S.2
George, A.3
Torigian, D.4
Duhaney, M.5
Snyder, P.6
-
53
-
-
0036153570
-
Long-term effects of lanreotide SR and octreotide LARR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly
-
1
-
Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LARR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol 2002;56(1):65-71.
-
(2002)
Clin Endocrinol
, vol.56
, pp. 65-71
-
-
Amato, G.1
Mazziotti, G.2
Rotondi, M.3
Iorio, S.4
Doga, M.5
Sorvillo, F.6
-
54
-
-
0037381257
-
Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage
-
4
-
Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol 2003;58(4):471-81.
-
(2003)
Clin Endocrinol
, vol.58
, pp. 471-481
-
-
Lucas, T.1
Astorga, R.2
Catala, M.3
-
55
-
-
17144431786
-
Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel)
-
Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exper Clin Endocrinol Diabetes 2005;3:139-44.
-
(2005)
Exper Clin Endocrinol Diabetes
, vol.3
, pp. 139-144
-
-
Gutt, B.1
Bidlingmaier, M.2
Kretschmar, K.3
Dieterle, C.4
Steffin, B.5
Schopohl, J.6
-
56
-
-
0036148030
-
Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly
-
Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:99-104.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 99-104
-
-
Caron, P.1
Beckers, A.2
Cullen, D.R.3
Goth, M.I.4
Gutt, B.5
Laurberg, P.6
-
57
-
-
2342485029
-
Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients
-
4
-
van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frolich M, Smit JW, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150(4):489-95.
-
(2004)
Eur J Endocrinol
, vol.150
, pp. 489-495
-
-
Van Thiel, S.W.1
Romijn, J.A.2
Biermasz, N.R.3
Ballieux, B.E.4
Frolich, M.5
Smit, J.W.6
-
58
-
-
4744375607
-
Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR
-
3
-
Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151(3):317-24.
-
(2004)
Eur J Endocrinol
, vol.151
, pp. 317-324
-
-
Alexopoulou, O.1
Abrams, P.2
Verhelst, J.3
Poppe, K.4
Velkeniers, B.5
Abs, R.6
-
59
-
-
21044441388
-
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles
-
7
-
Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45(7):836-44.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 836-844
-
-
Astruc, B.1
Marbach, P.2
Bouterfa, H.3
Denot, C.4
Safari, M.5
Vitaliti, A.6
-
60
-
-
33845491265
-
Acromegaly
-
24
-
Melmed S. Acromegaly. N Engl J Med 2006;355(24):2558-73.
-
(2006)
N Engl J Med
, vol.355
, pp. 2558-2573
-
-
Melmed, S.1
-
61
-
-
0033672781
-
Slow-release lanreotide in the treatment of acromegaly: A study in 66 patients
-
5
-
Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000;143(5):577-84.
-
(2000)
Eur J Endocrinol
, vol.143
, pp. 577-584
-
-
Verhelst, J.A.1
Pedroncelli, A.M.2
Abs, R.3
Montini, M.4
Vandeweghe, M.V.5
Albani, G.6
-
62
-
-
33745236035
-
Disappearance of a growth hormone secreting macroadenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal
-
1
-
Livadas S, Hadjidakis J, Argyropoulou M, Stamatelatou M, Kelekis D, Raptis S. Disappearance of a growth hormone secreting macroadenoma during long-term somatostatin analogue administration and recurrence following somatostatin withdrawal. Hormones (Athens) 2006 2007;5(1):57-63.
-
(2007)
Hormones (Athens) 2006
, vol.5
, pp. 57-63
-
-
Livadas, S.1
Hadjidakis, J.2
Argyropoulou, M.3
Stamatelatou, M.4
Kelekis, D.5
Raptis, S.6
-
64
-
-
9844264858
-
Effect of octreotide pretreatment on surgical outcome in acromegaly
-
10
-
Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82(10):3308-14.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 3308-3314
-
-
Colao, A.1
Ferone, D.2
Cappabianca, P.3
Del Basso De Caro, M.L.4
Marzullo, P.5
Monticelli, A.6
-
65
-
-
0031792509
-
Cabergoline in the treatment of acromegaly: A study in 64 patients
-
2
-
Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998;83(2):374-8.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 374-378
-
-
Abs, R.1
Verhelst, J.2
Maiter, D.3
Van Acker, K.4
Nobels, F.5
Coolens, J.L.6
-
66
-
-
0023164787
-
Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: A comparison with bromocriptine
-
3
-
Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 1987;64(3):447-53.
-
(1987)
J Clin Endocrinol Metab
, vol.64
, pp. 447-453
-
-
Chiodini, P.G.1
Cozzi, R.2
Dallabonzana, D.3
Oppizzi, G.4
Verde, G.5
Petroncini, M.6
-
67
-
-
0026328373
-
Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly
-
11
-
Plockinger O, Quabbe H. Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly. J Endocrinol Invest 1991;14(11):943-8.
-
(1991)
J Endocrinol Invest
, vol.14
, pp. 943-948
-
-
Plockinger, O.1
Quabbe, H.2
-
68
-
-
0016172045
-
Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration
-
5
-
Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 1974;38(5):910-2.
-
(1974)
J Clin Endocrinol Metab
, vol.38
, pp. 910-912
-
-
Liuzzi, A.1
Chiodini, P.G.2
Botalla, L.3
Cremascoli, G.4
Muller, E.E.5
Silvestrini, F.6
-
69
-
-
0016434731
-
Bromocriptine treatment of acromegaly
-
Thorner M, Chait A, Aitken M, Benker G, Bloom SR. Bromocriptine treatment of acromegaly. Br Med J 1975;1:299-303.
-
(1975)
Br Med J
, vol.1
, pp. 299-303
-
-
Thorner, M.1
Chait, A.2
Aitken, M.3
Benker, G.4
Bloom, S.R.5
-
70
-
-
0019509233
-
Bromocriptine therapy in acromegaly. a long-term review of 35 cases
-
666
-
Sachdev Y, Gopal K, Garg VK. Bromocriptine therapy in acromegaly. A long-term review of 35 cases. Postgrad Med J 1981;57(666):210-6.
-
(1981)
Postgrad Med J
, vol.57
, pp. 210-216
-
-
Sachdev, Y.1
Gopal, K.2
Garg, V.K.3
-
71
-
-
0026701677
-
Treatment of acromegaly with dopamine agonists
-
3
-
Jaffe C, Barkan A. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21(3):713-35.
-
(1992)
Endocrinol Metab Clin North Am
, vol.21
, pp. 713-735
-
-
Jaffe, C.1
Barkan, A.2
-
72
-
-
0019432836
-
No effect of bromocriptine in acromegaly: A controlled trial
-
24
-
Lindholm J, Riishede J, Vestergaard S, Hummer L, Faber O, Hagen C. No effect of bromocriptine in acromegaly: a controlled trial. N Engl J Med 1981;304(24):1450-4.
-
(1981)
N Engl J Med
, vol.304
, pp. 1450-1454
-
-
Lindholm, J.1
Riishede, J.2
Vestergaard, S.3
Hummer, L.4
Faber, O.5
Hagen, C.6
-
73
-
-
0021276136
-
Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests
-
May (5)
-
Nortier J, Croughs R, Thijssen J, Schwarz F. Plasma growth hormone suppressive effect of bromocriptine in acromegaly. Evaluation by plasma GH day profiles and plasma GH concentrations during oral glucose tolerance tests. Clin Endocrinol 1984;20 May (5):565-71.
-
(1984)
Clin Endocrinol
, vol.20
, pp. 565-571
-
-
Nortier, J.1
Croughs, R.2
Thijssen, J.3
Schwarz, F.4
-
74
-
-
0019471258
-
Treatment results in 235 patients with acromegaly. a report of the acromegaly study group
-
Suppl
-
Quabbe H. Treatment results in 235 patients with acromegaly. A report of the acromegaly study group. Acta Endocrinol (Copenh). 1981;240 Suppl:66.
-
(1981)
Acta Endocrinol (Copenh).
, vol.240
, pp. 66
-
-
Quabbe, H.1
-
75
-
-
33749865531
-
Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study
-
7
-
Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study. Neurology 2006;67(7):1225-9.
-
(2006)
Neurology
, vol.67
, pp. 1225-1229
-
-
Yamamoto, M.1
Uesugi, T.2
Nakayama, T.3
-
76
-
-
0025322555
-
Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice
-
13
-
Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 1990;87(13):5061-5.
-
(1990)
Proc Natl Acad Sci USA
, vol.87
, pp. 5061-5065
-
-
Chen, W.Y.1
Wight, D.C.2
Wagner, T.E.3
Kopchick, J.J.4
-
77
-
-
0026764441
-
Rational design of potent antagonists to the human growth hormone receptor
-
5064
-
Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992;256(5064):1677-80.
-
(1992)
Science
, vol.256
, pp. 1677-1680
-
-
Fuh, G.1
Cunningham, B.C.2
Fukunaga, R.3
Nagata, S.4
Goeddel, D.V.5
Wells, J.A.6
-
78
-
-
0034690311
-
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
-
16
-
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-7.
-
(2000)
N Engl J Med
, vol.342
, pp. 1171-1177
-
-
Trainer, P.J.1
Drake, W.M.2
Katznelson, L.3
Freda, P.U.4
Herman-Bonert, V.5
Van Der Lely, A.J.6
-
79
-
-
0035944825
-
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
-
9295
-
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754-9.
-
(2001)
Lancet
, vol.358
, pp. 1754-1759
-
-
Van Der Lely, A.J.1
Hutson, R.K.2
Trainer, P.J.3
Besser, G.M.4
Barkan, A.L.5
Katznelson, L.6
-
80
-
-
18744389775
-
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
-
9471
-
Feenstra J, de Herder WW, ten Have SMTH, van den Beld AW, Feelders RA, Janssen JAMJ, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. The Lancet 2005;365(9471):1644-6.
-
(2005)
The Lancet
, vol.365
, pp. 1644-1646
-
-
Feenstra, J.1
De Herder, W.W.2
Have Smth, T.3
Van Den Beld, A.W.4
Feelders, R.A.5
Jamj, J.6
-
81
-
-
33847700931
-
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
-
1
-
Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156(1):75-82.
-
(2007)
Eur J Endocrinol
, vol.156
, pp. 75-82
-
-
Schreiber, I.1
Buchfelder, M.2
Droste, M.3
Forssmann, K.4
Mann, K.5
Saller, B.6
-
82
-
-
36849041110
-
Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly
-
(in press).
-
Neggers SJCM, van Aken MO, Janssen JAMJ, Feelders RA, de Herder WW, van der Lely A-J. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007 (in press).
-
(2007)
J Clin Endocrinol Metab
-
-
Neggers, S.J.C.M.1
Van Aken, M.O.2
Janssen, J.A.M.J.3
Feelders, R.A.4
De Herder, W.W.5
Van Der Lely, A.-J.6
-
83
-
-
10744231363
-
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
-
2
-
van der Hoek J, de Herder WW, Feelders RA, van der Lely A-J, Uitterlinden P, Boerlin V, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89(2):638-45.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 638-645
-
-
Van Der Hoek, J.1
De Herder, W.W.2
Feelders, R.A.3
Van Der Lely, A.-J.4
Uitterlinden, P.5
Boerlin, V.6
-
84
-
-
17644382943
-
GH Receptor antagonist: Mechanism of action and clinical utility
-
1
-
Surya S, Barkan A. GH Receptor antagonist: mechanism of action and clinical utility. Rev Endoc Metab Disord 2005;6(1):5-13.
-
(2005)
Rev Endoc Metab Disord
, vol.6
, pp. 5-13
-
-
Surya, S.1
Barkan, A.2
-
85
-
-
0242572132
-
Dimerization of G-protein-coupled receptors: Roles in signal transduction
-
2
-
Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell Signal 2004;16(2):175-86.
-
(2004)
Cell Signal
, vol.16
, pp. 175-186
-
-
Bai, M.1
-
86
-
-
14644387575
-
Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation
-
3
-
Bulenger S, Marullo S, Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005;26(3):131-7.
-
(2005)
Trends Pharmacol Sci
, vol.26
, pp. 131-137
-
-
Bulenger, S.1
Marullo, S.2
Bouvier, M.3
-
87
-
-
34249090218
-
Novel chimeric somatostatin analogs: Facts and perspectives
-
suppl_1
-
Ferone D, Saveanu A, Culler MD, Arvigo M, Rebora A, Gatto F, et al. Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007;156 suppl_1:S23-8.
-
(2007)
Eur J Endocrinol
, vol.156
-
-
Ferone, D.1
Saveanu, A.2
Culler, M.D.3
Arvigo, M.4
Rebora, A.5
Gatto, F.6
-
88
-
-
0034616021
-
Receptors for dopamine and somatostatin: Formation of Hetero-Oligomers with enhanced functional activity
-
5463
-
Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of Hetero-Oligomers with enhanced functional activity. Science 2000;288(5463):154-7.
-
(2000)
Science
, vol.288
, pp. 154-157
-
-
Rocheville, M.1
Lange, D.C.2
Kumar, U.3
Patel, S.C.4
Patel, R.C.5
Patel, Y.C.6
|